Role of Insulin Resistance in MAFLD
Open accessThe DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Abstract
Many studies have reported that metabolic dysfunction is closely involved in the complex mechanism underlying the development of non-alcoholic fatty liver disease (NAFLD), which has prompted a movement to consider renaming NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD). Metabolic dysfunction in this context encompasses obesity, type 2 diabetes mellitus, hypertension, dyslipidemia, and metabolic syndrome, with insulin resistance as the common underlying pathophysiology. Imbalance between energy intake and expenditure results in insulin resistance in various tissues and alteration of the gut microbiota, resulting in fat accumulation in the liver. The role of genetics has also been revealed in hepatic fat accumulation and fibrosis. In the process of fat accumulation in the liver, intracellular damage as well as hepatic insulin resistance further potentiates inflammation, fibrosis, and carcinogenesis. Increased lipogenic substrate supply from other tissues, hepatic zonation of Irs1, and other factors, including ER stress, play crucial roles in increased hepatic de novo lipogenesis in MAFLD with hepatic insulin resistance. Herein, we provide an overview of the factors contributing to and the role of systemic and local insulin resistance in the development and progression of MAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Given that insulin resistance (IR) is widely recognized as the key underlying mechanism of metabolic syndrome, it is reasonable to consider IR as a central factor in the pathogenesis of MASLD, which can be viewed as the hepatic manifestation of metabolic syndrome [2,9-12].”
The cited source says what the claim attributes to it.
In the citing paper
“ChREBP, which is activated by carbohydrate uptake [9,34,78,83].”
The cited source says what the claim attributes to it.
In the citing paper
“Among the core insulin signaling mediators—including INSR, IRS1, IRS2, AKT1, and AKT2—IRS1 shows marked zonal expression, with approximately 2-fold higher levels in PV compared to PP regions [9,20].”
In the citing paper
“Many studies have shown that insulin- resistant conditions are accompanied by a substantial increase in MTP and apolipoprotein C3 (ApoCIII) expression and the production of hepatic VLDL-ApoB and VLDL-TG [2, 9,108,111].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
MORA, A., LIPINA, C., TRONCHE, F., SUTHERLAND, C., & ALESSI, D. R. (2005) · Biochemical Journal · doi:10.1042/bj20041782 · Cited by 92
RetractedSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · cited 2×
“, hepatocyte ballooning), with or without fibrosis [2].”
BackgroundMetabolic Endotoxemia Initiates Obesity and Insulin Resistance
Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A. M., Fava, F., Tuohy, K. M., Chabo, C., et al. (2007) · Diabetes · doi:10.2337/db06-1491 · Cited by 6,638
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“The global prevalence of NAFLD is estimated at 24%; the highest rates are reported from South America and the Middle East, followed by Asia, the USA, and Europe [3].”
BackgroundSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Cited by
Current status and future trends of the global burden of MASLD
Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y., & Zheng, M.-H. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.02.007 · Cited by 781
Guo, X., Yin, X., Liu, Z., & Wang, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415489 · Cited by 412
Bo, T., Gao, L., Yao, Z., Shao, S., Wang, X., Proud, C. G., & Zhao, J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.006 · Cited by 293
Zheng, H., Sechi, L. A., Navarese, E. P., Casu, G., & Vidili, G. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02434-5 · Cited by 185
Chu, Y., Yang, M., Meng, Q., Cong, D., Xu, L., Dai, P., Chen, Z., Chen, S., Zhang, R., & Leng, Y. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-025-01065-1 · Cited by 181
Eslam, M., Fan, J.-G., Yu, M.-L., Wong, V. W.-S., Cua, I. H., Liu, C.-J., Tanwandee, T., Gani, R., Seto, W.-K., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 170
Zhou, X.-D., Cai, J., Targher, G., Byrne, C. D., Shapiro, M. D., Sung, K.-C., Somers, V. K., Chahal, C. A. A., George, J., Chen, L.-L., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01697-0 · Cited by 168
Ubiquitin-Specific Proteases (USPs) and Metabolic Disorders
Kitamura, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043219 · Cited by 157
Chen, Q., Hu, P., Hou, X., Sun, Y., Jiao, M., Peng, L., Dai, Z., Yin, X., Liu, R., Li, Y., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02343-7 · Cited by 155
Management of diabesity: Current concepts
Michaelidou, M., Pappachan, J. M., & Jeeyavudeen, M. S. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i4.396 · Cited by 148
Palma, R., Pronio, A., Romeo, M., Scognamiglio, F., Ventriglia, L., Ormando, V. M., Lamazza, A., Pontone, S., Federico, A., & Dallio, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133649 · Cited by 125
Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease
Yin, X., Guo, X., Liu, Z., & Wang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032844 · Cited by 102
Ferroptosis and metabolic dysfunction‐associated fatty liver disease: Is there a link?
Feng, G., Byrne, C. D., Targher, G., Wang, F., & Zheng, M. (2022) · Liver International · doi:10.1111/liv.15163 · Cited by 101
Park, J.-S., Rustamov, N., & Roh, Y. (2023) · Antioxidants · doi:10.3390/antiox12111928 · Cited by 95
Cól, J. P. D., de Lima, E. P., Pompeu, F. M., Araújo, A. C., Goulart, R. D. Á., Bechara, M. D., Laurindo, L. F., Méndez‐Sánchez, N., & Barbalho, S. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073694 · Cited by 92
Insulin Resistance Is Cheerfully Hitched with Hypertension
Sinha, S., & Haque, M. (2022) · Life · doi:10.3390/life12040564 · Cited by 86
Truong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“Insulin receptor substrate 1 (IRS1) and IRS2 among IRS1–6 are the main adaptor proteins in the liver, activating phosphatidylinositol-3 kinase (PI3K) [9,11,15,19].”
InfluentialAn, H., Jang, Y., Choi, J.-I., Hur, J., Kim, S., & Kwon, Y. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.188 · Cited by 80
Cao, X., Wang, N., Yang, M. J., & Zhang, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146962 · Cited by 79
Interferon Family Cytokines in Obesity and Insulin Sensitivity
Huang, L.-Y., Chiu, C.-J., Hsing, C., & Hsu, Y. (2022) · Cells · doi:10.3390/cells11244041 · Cited by 65
Li, X., Chen, W., Jia, Z., Xiao, Y., Shi, A., & Ma, X. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094256 · Cited by 63
Zeng, J., Qin, L., Jin, Q., Yang, R., Ning, G., Su, Q., YANG, Z. K., & Fan, J. (2022) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2022.01.006 · Cited by 59
Gudan, A., Kozłowska‐Petriczko, K., Wunsch, E., Bodnarczuk, T., & Stachowska, E. (2023) · Nutrients · doi:10.3390/nu15061323 · Cited by 58
Suresh, M. G., Mohamed, S., Geetha, H. S., Prabhu, S., Trivedi, N., Mehta, P. D., Damodaran, U. K., Brar, A., Sohal, A., Hatwal, J., et al. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2025.0212 · Cited by 55
Associations Between GGT/HDL and MAFLD: A Cross-Sectional Study
Xing, Y., Chen, J., Liu, J., & Ma, H. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s342505 · Cited by 55
Pan, Z., Mao, B., Zhang, Q., Tang, X., Yang, B. K., Zhao, J., Cui, S., & Zhang, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113522 · Cited by 53
Cioffi, F., Giacco, A., Petito, G., Matteis, R. D., Senese, R., Lombardi, A., de Lange, P., Moreno, M., Goglia, F., Lanni, A., et al. (2022) · Genes · doi:10.3390/genes13020315 · Cited by 53
Zhang, Y., Wu, J., Li, T., Qu, Y., & Wang, Y. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02616-9 · Cited by 52
Jiang, Y., Wu, L., Zhu, X., Bian, H., Gao, X., & Xia, M. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02092-2 · Cited by 50
Cao, F., Ding, Q., Zhuge, H., Lai, S., Chang, K., Le, C., Yang, G., Valencak, T. G., Li, S., & Ren, D. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1071284 · Cited by 49
Detangling the interrelations between MAFLD, insulin resistance, and key hormones
Pal, S. C., Eslam, M., & Méndez‐Sánchez, N. (2022) · HORMONES · doi:10.1007/s42000-022-00391-w · Cited by 49
Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances
Ding, Z., Wang, L., Sun, J., Zheng, L., Tang, Y., & Tang, H. H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1526206 · Cited by 49
Wasiak, J., & Gawlik-Kotelnicka, O. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114459 · Cited by 47
Liu, Y., Hao, C., Li, L., Zhang, H., Zha, W., Longbin, M., Chen, L., & Gan, J. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230418121130 · Cited by 47
Abenavoli, L., Scarlata, G. G. M., Scarpellini, E., Boccuto, L., Spagnuolo, R., Tilocca, B., Roncada, P., & Luzza, F. (2023) · Medicina · doi:10.3390/medicina59030594 · Cited by 47
Ali, H., Shahzil, M., Moond, V., Shahzad, M., Thandavaram, A., Sehar, A., Waseem, H., Siddiqui, T. A., Dahiya, D. S., Patel, P., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010061 · Cited by 46
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Petagine, L., Zariwala, M. G., & Patel, V. B. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i32.4831 · Cited by 45
Zhang, J.-J., Yu, H., Li, Y., Zhang, Y., Geng, T., Lu, Q., Liao, Y.-F., Guo, K., Du, L., Ruan, H.-L., et al. (2022) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac260 · Cited by 44
Autophagy and senescence: the molecular mechanisms and implications in liver diseases
Li, Q., Lin, Y., Liang, G., Xiao, N., Zhang, H., Yang, X., Yang, J., & Liu, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316880 · Cited by 43
“Insulin resistance is the main mechanism of NAFLD development [69].”
BackgroundZhang, Z., Yang, H., Han, F., & Guo, P. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47060464 · Cited by 43
Mohiuddin, M. S., Neha, N. T., Mahir, J. U. K., Shakib, F. A. F., Alam, M. A., Wahiduzzaman, M., Barua, R., Shimu, S. J., Rahman, M. M., Hossain, M. R., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1669478 · Cited by 43
Yuan, H., Jung, E.-S., Chae, S., Jung, S., Daily, J. W., & Park, S. (2024) · Nutrients · doi:10.3390/nu16183061 · Cited by 42
Schwenger, K. J. P., Ghorbani, Y., Bharatselvam, S., Chen, L., Chomiak, K. M., Tyler, A. C., Eddingsaas, N. C., Fischer, S. E., Jackson, T. D., Okrainec, A., et al. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.176153 · Cited by 41
Ebrahimi, F., Simon, T. G., Hagström, H., Söderling, J. K., Wester, A., Roelstraete, B., & Ludvigsson, J. F. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.05.013 · Cited by 41
Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Santos‐Laso, Á., Gutiérrez‐Larrañaga, M., Alonso‐Peña, M., Medina, J. M., Iruzubieta, P., Arias, M., López‐Hoyos, M., & Crespo, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010046 · Cited by 40
Yan, H., Huang, C., Shen, X., Li, J., Zhou, S., & Li, W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.923606 · Cited by 38
Minetti, E. T., Hamburg, N. M., & Matsui, R. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1469492 · Cited by 38
Mladenović, D. R., Vesković, M. N., Šutulović, N., Hrnčić, D., Stanojlović, O. P., Radić, L., Macut, J. B., & Μacut, D. (2024) · Endocrine · doi:10.1007/s12020-024-03702-w · Cited by 37
Song, Z., Bu, S., Sang, S., Li, J., Zhang, X., Song, X., & Ran, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s514498 · Cited by 37
Jeong, C., Han, N., Jeon, N., Rhee, S., Staatz, C. E., Kim, M., & Baek, I. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3278 · Cited by 36
Complex impacts of gallstone disease on metabolic syndrome and nonalcoholic fatty liver disease
Lyu, J., Lin, Q., Fang, Z., Xu, Z., & Liu, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032557 · Cited by 36
Metabolic-Associated Fatty Liver Disease and the Gut Microbiota
Barber, T. M., Hanson, P., & Weickert, M. O. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.01.004 · Cited by 36
Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Dong, Q., Bao, H., Wang, J., Shi, W., Zou, X., Sheng, J., Gao, J., Guan, C., Xia, H., Li, J., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1120621 · Cited by 35
Deciphering the role of aberrant DNA methylation in NAFLD and NASH
Vachher, M., Bansal, S., Kumar, B., Yadav, S., & Burman, A. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11119 · Cited by 34
Research progress on drugs for diabetes based on insulin receptor/insulin receptor substrate
Su, J., Tang, L., Luo, Y., Xu, J., & Ouyang, S. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115830 · Cited by 33
Sphingosine 1-Phosphate Regulates Obesity and Glucose Homeostasis
Kajita, K., Ishii, I., Mori, I., Asano, M., Fuwa, M., & Morita, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020932 · Cited by 33
Jia, J., Zhai, S., Cai, T., Guo, P., Yang, G., Chang, Z., Chen, Y., Song, X., Lu, X., Chu, L., et al. (2026) · Food Science and Human Wellness · doi:10.26599/fshw.2025.9250908 · Cited by 33
Polyphenol consumption and Nonalcoholic fatty liver disease risk in adults
Rahimlou, M., Baghdadi, G., Khodi, A., Rahimi, Z., Saki, N., Banaei-Jahromi, N., Cheraghian, B., Tavasolian, R., & Hosseini, S. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-57416-0 · Cited by 32
Abassi, W., Ouerghi, N., Hammami, M. B., Jebabli, N., Feki, M., Bouassida, A., Weiss, K., & Knechtle, B. (2025) · Nutrients · doi:10.3390/nu17010164 · Cited by 32
Preventative and Therapeutic Effects of Astaxanthin on NAFLD
Sayuti, N. H., Nawawi, K. N. M., Goon, J. A., Mokhtar, N. M., Makpol, S., & Tan, J. K. (2023) · Antioxidants · doi:10.3390/antiox12081552 · Cited by 31
Fang, X., Song, J., Zhou, K., Zi, X., Sun, B., Bao, H., & Li, L. (2023) · Molecules · doi:10.3390/molecules28155645 · Cited by 30
Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
Li, Y., Qi, P., Song, S., Wang, Y., Wang, H., Cao, P., Liu, Y., & Wang, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116585 · Cited by 30
Efrem, I. C., Moța, M., Vladu, I. M., Mitrea, A., Clenciu, D., Timofticiuc, D. C. P., Diaconu, I.-D., Turcu, A. A., Crișan, A. E., Geormăneanu, C., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12102426 · Cited by 30
Niu, C., Tu, Y., Jin, Q., Chen, Z., Yuan, K., Wang, M., Zhang, P., Luo, J., Li, H., Yang, Y., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1157368 · Cited by 30
Shen, D., Cai, X., Hu, J., Song, S., Zhu, Q., Ma, H., Zhang, Y., Ma, R., Zhou, P., Yang, W., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s503648 · Cited by 30
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Gong, B., Yao, Z., Zhou, C., Wang, W., Sun, L., & Han, J. D. J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116342 · Cited by 29
Cheng, P., Chen, W., Hou, C. J., Lin, C., Chang, M., Wang, C., Chang, W., Wang, C., Lin, C., Hung, C., et al. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0315 · Cited by 29
Lu, Z., Zheng, Y., Zheng, J., Liang, Q., Zhen, Q., Cui, M., Yang, H., Wu, H., Tian, C., Zhu, K., et al. (2024) · Food & Function · doi:10.1039/d3fo05459d · Cited by 29
Ma, Y.-L., Ke, J.-F., Wang, J., Wang, Y., Xu, M.-R., & Li, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1133991 · Cited by 28
Association between hypertension and the prevalence of liver steatosis and fibrosis
Fu, H., Yu, H., Zhao, Y., Chen, J., & Liu, Z. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01318-1 · Cited by 28
Gualou-Xiebai-Banxia-Tang regulates liver-gut axis to ameliorate Metabolic Syndrome in HFD-fed mice
Zhang, Y., Zhang, L., Li, Z., Liu, X., He, P., Gu, Y., Liu, L., Jin, Y., Cheng, S., Zhou, F., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2023.155320 · Cited by 28
The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists
Khan, M. S., Javaid, S. S., Dinani, A. M., Wegermann, K., Pandey, A., Bhatt, A. S., Muthiah, M. D., Spall, H. G. C. V., Zannad, F. M., Butler, J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.100 · Cited by 27
Núñez‐Sánchez, M. Á., Martínez‐Sánchez, M. A., Martínez‐Montoro, J. I., Román, A. B., García, E. M., Fernández-Ruiz, V. E., Ferrer‐Gómez, M., Martínez, C. M., Śledziński, T., Frutos, M. D., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae028 · Cited by 27
Nonalcoholic Fatty Liver Disease—A Concise Review of Noninvasive Tests and Biomarkers
Bassal, T., Basheer, M., Boulos, M., & Assy, N. (2022) · Metabolites · doi:10.3390/metabo12111073 · Cited by 27
Wayal, V., Wang, S.-D., & Hsieh, C. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114177 · Cited by 26
Boulos, M., Mousa, R. S., Jeries, N., Simaan, E., Alam, K., Bulus, B., & Assy, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073448 · Cited by 26
Leca, B. M., Lagojda, L., Kite, C., Karteris, E., Kassi, E. N., Randeva, H. S., & Kyrou, I. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2365791 · Cited by 26
Nutritional Support for Liver Diseases
Jamioł-Milc, D., Gudan, A., Kaźmierczak-Siedlecka, K., Hołowko, J., Maciejewska, D., Janda, K., & Stachowska, E. (2023) · Nutrients · doi:10.3390/nu15163640 · Cited by 26
What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications
Ramírez-Mejía, M. M., & Méndez‐Sánchez, N. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00620-9 · Cited by 25
Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks
Barber, T. M., Kabisch, S., Pfeiffer, A. F. H., & Weickert, M. O. (2023) · Metabolites · doi:10.3390/metabo13060757 · Cited by 24
Barbhuiya, P. A., Sen, S., & Pathak, M. P. (2023) · Phytochemistry Reviews · doi:10.1007/s11101-023-09912-w · Cited by 24
Maddie, N., Chacko, N., Matatov, D., & Carrillo-Sepúlveda, M. A. (2024) · Physiological Reports · doi:10.14814/phy2.70139 · Cited by 24
Bian, S., Zhu, S., Lu, J., Iqbal, M., Jamil, T., Kiani, F. A., Dong, H., Dai, H., Zhang, X., Liu, F., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147995 · Cited by 24
Liu, H., Xing, Y., Nie, Q., Li, Z., Meng, C., & Ma, H. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s420872 · Cited by 24
Yan, B., Zheng, X., Wang, Y., Yang, J., Zhu, X., Qiu, M., Xia, K., Wang, Y., Li, M., Li, S., et al. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00210 · Cited by 24
Zhu, J., Guo, J., Liu, Z., Liu, J., Yuan, A., Chen, H., Qiu, J., Dou, X., Lu, D., & Le, Y. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111162 · Cited by 24
Zhang, H., Wu, D., Wu, Q., Wu, Y., Guo, Z., Wang, L., Wang, Y., Zeng, Q., Shi, L., Shi, B., et al. (2025) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2025.00259 · Cited by 24
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Khaznadar, F., Khaznadar, O., Petrovic, A., Hefer, M., Gjoni, F., Gjoni, S., Steiner, J., Smolić, M., & Bojanić, K. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070376 · Cited by 23
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
Hao, C. H. E. N., Zhou, Y., Hao, H., & XIONG, J. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60690-4 · Cited by 23
Wang, H., Liu, X., Wang, C., Yu, S., Yang, X., Cao, X., Luo, M., Liu, S., & Zhang, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1611400 · Cited by 23
Huang, J., Chen, L., Li, X., Chen, M., Lin, T., & Chen, G. (2023) · Nature and Science of Sleep · doi:10.2147/nss.s398971 · Cited by 23
Vural, H., Armutçu, F., Akyol, Ö., & Weiskirchen, R. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.10.018 · Cited by 23
Januario, E., Barakat, A., Rajsundar, A., Fatima, Z., Palienkar, V. N., Bullapur, A. V., Brar, S. S., Kharel, P., Machingal, M. M. K., & Backosh, A. (2024) · Cureus · doi:10.7759/cureus.75677 · Cited by 23
Li, B., Jiang, X., Dong, Y., Zhang, Y.-P., He, X., Zhou, C., Ding, Y.-Y., Wang, N., Wang, Y.-B., Cheng, W.-Q., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116519 · Cited by 23
Zhu, Y., Chen, L., He, Y., Qin, L., Tan, D., Bai, Z., Song, Y., & Wang, Y.-H. (2023) · Drug Metabolism Reviews · doi:10.1080/03602532.2023.2202359 · Cited by 23
Ma, K., Sheng, W., Gao, R., Feng, J., Huang, W., Cui, L., Liu, J., & Li, Y. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14455 · Cited by 23
Advances in genetic variation in metabolism-related fatty liver disease
Shi, F., Zhao, M., Zheng, S., Zheng, L., & Wang, H. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1213916 · Cited by 22
Yan, B., Pan, L.-F., Quan, Y.-F., Sha, Q., Zhang, J.-Z., Zhang, Y., Zhou, L., Qian, X.-L., Gu, X., Li, F., et al. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i31.4744 · Cited by 22
Non-alcoholic fatty liver disease: Dietary and nutraceutical approaches
Cogorno, L., Formisano, E., Vignati, A., Prigione, A., Tramacere, A., Borgarelli, C., Sukkar, S. G., & Pisciotta, L. (2023) · Liver Research · doi:10.1016/j.livres.2023.08.005 · Cited by 22
Metabolic-associated fatty liver disease and sarcopenia: A double whammy
Viswanath, A., Fouda, S., Fernandez, C. J., & Pappachan, J. M. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i2.152 · Cited by 22
Metadata
- Authors
- Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T.
- Affiliations
- The University of Tokyo (JP)
- National Institute of Biomedical Innovation, Health and Nutrition (JP)
- Toranomon Hospital (JP)
- Corresponding author
- Kubota, Naoto
- Kadowaki, Takashi
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-16
- Volume
- 22
- Issue
- 8
- Pages
- 4156
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8072900
- OpenAlex
- W3155254720
- Cited by
- 448
- References
- 195
- Citations by year
- 2026: 72 · 2025: 129 · 2024: 125 · 2023: 80 · 2022: 37 · 2021: 5
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Japan Society for the Promotion of Science (19K17977)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- non-alcoholic fatty liver disease, insulin resistance, hepatic insulin resistance, hepatic steatosis, liver fibrosis, de novo lipogenesis, gut microbiota, metabolic syndrome, obesity, type 2 diabetes, endoplasmic reticulum stress, liver inflammation, hepatocarcinogenesis
- MeSH terms
- Animals, Humans, Insulin, Signal Transduction, Metabolic Syndrome, Lipogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.